Skip to main content
. 2018 Jan 8;36(6):554–562. doi: 10.1200/JCO.2017.74.5034

Table 2.

Chemotherapy Rates by Age and Oncotype DX Test Use and Recurrence Outcomes in Community Practice With Testing and Usual Care in the Pre–Oncotype DX Era Among Patients with Stage I or IIa, Node-Negative, ER-Positive/HER2-Negative Breast Cancer

graphic file with name JCO.2017.74.5034t2.jpg